logo
Twitter
Discord
Email
logo
Quipt Home Medical Corp.

Quipt Home Medical Corp.

NASDAQ•QIPT
CEO: Mr. Gregory J. Crawford
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2010-08-10
Quipt Home Medical Corp., through its subsidiaries, engages in the provision of durable and home medical equipment and supplies in the United States. The company offers nebulizers, oxygen concentrators, and CPAP and BiPAP units; traditional and non-traditional durable medical respiratory equipment and services; non-invasive ventilation equipment, supplies, and services; and engages in the rental of medical equipment. It offers management of various chronic disease states focusing on patients with heart and pulmonary disease, sleep apnea, reduced mobility, and other chronic health conditions. The company was formerly known as Protech Home Medical Corp. and changed its name to Quipt Home Medical Corp. in May 2021. Quipt Home Medical Corp. is headquartered in Wilder, Kentucky.
Contact Information
1019 Town Drive, Wilder, KY, 41076, United States
859-878-2220
quipthomemedical.com
Market Cap
$158.06M
P/E (TTM)
-14.5
32.4
Dividend Yield
--
52W High
$3.61
52W Low
$1.35
52W Range
99%
Rank50Top 68.9%
3.1
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$79.40M+24.12%
4-Quarter Trend

EPS

-$0.07+76.75%
4-Quarter Trend

FCF

$4.43M-54.10%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

FY2025 Revenue Flat Total revenues $245.36M, down 0.2% for FY2025; acquisitions contributed $7.3M quarterly, offsetting headwinds.
Key Acquisitions Completed Acquired Mediserve fully and 60% interest in Hart during September 2025; integration focus now paramount for scale.
Acquisition Agreement Signed Entered agreement to be acquired by Kingswood affiliates for US$3.65 per Share; closing expected first half 2026.

Risk Factors

Payor Reimbursement Pressure Discontinuation of Medicare 75/25 blended rate negatively impacted revenue and operating results for the fiscal year ended September 30, 2025.
Cybersecurity Incident Impact Change Healthcare incident hindered claims processing and collections, causing estimated $8.5M revenue impact over twelve months.
Inflation and Interest Costs Inflation increased material, labor, and transportation costs; variable rate debt exposes interest expense to rate volatility.
Regulatory Scrutiny Risks Subject to ongoing DOJ investigation regarding CPAP equipment claims submission; potential for substantial penalties exists.

Outlook

FY2026 Profitability Focus Priority for fiscal year 2026 is generating operating profit, positive cash flow, and growth in Adjusted EBITDA of $55.95M.
Continued M&A Expansion Strategy centers on leveraging business platforms to expand geographically and grow through synergistic DME/HME acquisitions.
Transaction Closing Expected Acquisition expected to close first half 2026, resulting in de-listing from Nasdaq and becoming a privately held company.

Peer Comparison

Revenue (TTM)

Lucid Diagnostics Inc.LUCD
$1.21B
+28885.2%
Quipt Home Medical Corp.QIPT
$250.78M
+0.2%
Xtant Medical Holdings, Inc.XTNT
$133.08M
+16.9%

Gross Margin (Latest Quarter)

MacroGenics, Inc.MGNX
81.6%
-16.7pp
Quipt Home Medical Corp.QIPT
74.5%
+0.6pp
Xtant Medical Holdings, Inc.XTNT
66.1%
+7.8pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
PRE$208.09M-4.7-28.9%1.1%
APYX$163.71M-11.2-153.8%68.4%
QIPT$158.06M-14.5-9.5%39.1%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
14.7%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Feb 9, 2026
|
EPS:-
|
Revenue:$104.46M
Reports
All Years

  • Form 10-K - FY 2025

    Period End: Sep 30, 2025|Filed: Dec 15, 2025|
    Revenue: $245.36M-0.2%
    |
    EPS: $-0.24-50.0%
    Miss

  • Form 10-Q - Q3 2025

    Period End: Jun 30, 2025|Filed: Aug 11, 2025|
    Revenue: $79.40M+24.1%
    |
    EPS: $-0.07+76.8%
    Beat

  • Form 10-Q - Q2 2025

    Period End: Mar 31, 2025|Filed: May 12, 2025|
    Revenue: $57.38M-6.3%
    |
    EPS: $-0.07+303.4%
    Miss

  • Form 10-Q - Q1 2025

    Period End: Dec 31, 2024|Filed: Feb 10, 2025|
    Revenue: $61.38M-1.9%
    |
    EPS: $-0.03-30.6%
    Beat

  • Form 10-K - FY 2024

    Period End: Sep 30, 2024|Filed: Dec 16, 2024|
    Revenue: $245.92M+16.2%
    |
    EPS: $-0.16-128.6%
    Miss

  • Form 40-F/A - FY 2023

    Period End: Sep 30, 2023|Filed: Apr 2, 2024|
    Revenue: $211.68M+51.3%
    |
    EPS: $-0.07-150.0%
    Miss

  • Form 40-F - FY 2023

    Period End: Sep 30, 2023|Filed: Dec 22, 2023|Refer to amended data

  • Form 40-F - FY 2022

    Period End: Sep 30, 2022|Filed: Dec 23, 2022|
    Revenue: $139.86M+36.6%
    |
    EPS: $0.14+170.0%
    Beat